Status:
RECRUITING
Analysis of Circulating Tumor DNA Dynamics to Predict and Monitor Response to TKI in Patients With Advanced NSCLC.
Lead Sponsor:
Gene Solutions
Conditions:
Non Small Cell Lung Cancer
Stage IIIB Non-small Cell Lung Cancer
Eligibility:
All Genders
18-80 years
Brief Summary
This is an observational study, aiming to investigate whether the ctDNA dynamics analyzed by the K-TrackTM assay could predict early response to Tyrosine kinase inhibitors (TKIs) in patients with adva...
Detailed Description
This study is recruiting female and male patients, aged 18 and older: * Who are diagnosed with advanced non-small cell lung cancer and indicated for TKI (first or second line). TKI combined with chem...
Eligibility Criteria
Inclusion
- Patients are diagnosed with advanced non-small cell lung cancer and indicated for TKI (first or second line). TKI combined with chemotherapy is allowed.
- FFPE/FNA sample is available.
- Compliant with treatment protocol.
- Patients consented to participate in the study.
Exclusion
- Patients already started TKI before enrollment.
- Patients already started chemotherapy before enrollment.
- Medical or psychiatric conditions or occupational responsibilities that may preclude compliance with the protocol.
- Patients did not agree to participate in the studies.
Key Trial Info
Start Date :
December 4 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06167460
Start Date
December 4 2023
End Date
December 1 2025
Last Update
July 16 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical Genetics Institute
Ho Chi Minh City, Vietnam